Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck

Perry, David J.; Weltz, Martin D.; Brown, Archie W.; Henderson, Robert L.; Neglia, William J.; Berenberg, Jeffrey L.

doi:10.1002/1097-0142(19821201)50:11<2257::aid-cncr2820501104>3.0.co;2-0

Cited by 19 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the small numbers of patients in these studies and the variety of drug regimens used, most of these trials report significant tumor regressions in 60% to 100% of patients and complete clinical disappearance of tumors in 10% to 50% of patien~s.9.17,19-21.28-31.37. 38 Many trials also suggest that correlations exist among degree of tumor regression, response to subsequent therapy,20*30,39 and improved survival. I7.19.21.38.40 0 ther studies suggest no benefit from such approaches in patients with advanced (Stage IV) or inoperable t~m o r s~' .…”

Section: Predictive Factors * Woffet Almentioning

confidence: 99%

Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program

Wolf¹,

Makuch²,

Baker³

1984

Cancer

View full text Add to dashboard Cite

The high tumor response rates associated with intensive chemotherapy in previously untreated patients with advanced head and neck squamous cell carcinoma (HNSCC) led to the initiation of a multi‐institutional National Cancer Institute trial. This trial used preoperative chemotherapy in patients with resectable Stage III and IV squamous cell carcinoma of the oral cavity or larynx/hypopharynx. Response rates, toxicity, and a variety of patient and tumor characteristics were analyzed to determine which factors might be useful in predicting tumor response to preoperative chemotherapy. Two hundred eighty‐two patients received one course of preoperative cisplatin and bleomycin chemotherapy and were evaluable. There were 22 complete responses (CR) and 114 partial responses (PR) at the primary site (48% response rate). Of 197 patients with clinically positive regional adenopathy, 29 CRs and 73 PRs were observed (52%). Toxicity associated with the chemotherapy regimen was minimal. Primary tumor and regional node responses to chemotherapy were strongly correlated. No significant differences were found in primary or nodal response rates with respect to differing tumor site, stage, histologic differentiation, patient performance status, nutritional status, leukocyte count, hemoglobin level, age, sex, or alcohol use. Primary tumor response, however, was significantly related to T classification (P = 0.048). Nodal response was strongly associated with N classification and nodal size (P = 0.02 and P = 0.075, respectively). These findings suggest that, of the patient and tumor characteristics analyzed, none were more useful in predicting tumor response than clinical tumor staging parameters.

show abstract

Section: Predictive Factors * Woffet Almentioning

confidence: 99%

Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program

Wolf¹,

Makuch²,

Baker³

1984

Cancer

View full text Add to dashboard Cite

show abstract

“…1) are used in combination chemotherapy to treat malignant melanoma (2), head-neck carcinoma (3), and testicular carcinoma (4). The two drugs exhibit synergism in the clinical management of head and neck cancer (5).…”

mentioning

confidence: 99%

Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II).

Mascharak¹,

Kuwahara²,

Suzuki³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The antitumor drug cis-diamminedichloroplatinum(II) dramatically alters the sequence-specific cleavage of the bleomycin Ar-iron(11)-02 system. Preferred bleomycin cleavage sites adjacent to oligo(dG) regions on two restriction fragments of plasmid pBR322 DNA were masked by pretreatment with cis-diamminedichloroplatinum(II). trans-Diamminedichloroplatinum-(II), which is inactive as an antitumor drug, showed similar but not identical behavior. The DNA-cleaving activity of bleomycin was substantially modified by cis-diamminedichloroplatinum(11), and a number of specific new cutting sites in guanine-rich parts of the sequence were activated by both isomers of the platinum complex. The -sults further emphasize the possibility that the synergism found when cis-diamminedichloroplatinum(II) and bleomycin are used in combination chemotherapy may be due to interactions at the level of DNA-drug binding.Bleomycin and cis-diamminedichloroplatinum(II) (cis-DDP) ( Fig. 1) are used in combination chemotherapy to treat malignant melanoma (2), head-neck carcinoma (3), and testicular carcinoma (4). The two drugs exhibit synergism in the clinical management of head and neck cancer (5). The biological target for both and bleomycin (7) is believed to be DNA.Bleomycin cleaves double-stranded DNA specifically at 5'-*3' G-C and G-T sequences in the presence of ferrous ion and molecular oxygen (1,(8)(9)(10)(11)(12), and the anticancer activity of this glycopeptide antibiotic is related to DNA strand scission. cis-DDP, on the other hand, binds covalently to DNA. Attachment of cis-DDP to poly(dG) regions through intrastrand crosslinking of guanosine N7 atoms is thought to be responsible for its various biological activities (13)(14)(15)(16)(17) DNA-Drug Reactions and Analysis. Reaction samples containing the 165-bp 32P-labeled DNA piece and sonicated calf thymus carrier DNA (1 mg/ml) were incubated with cis-or trans-DDP at a drug-to-nucleotide (D/N) mole ratio of 0.33, 0.165, 0.083, or 0.041 in 1 mM sodium phosphate/5 mM sodium chloride buffer, pH 7.4, at 37°C for 3 hr. In studies with the 327-bp fragment, the carrier DN and cis-DDP concentrations were 20 ,ug/ml and 40-,uM, respectively, corresponding to D/N = 0.67. Sodium chloride was added to 0.2 M final concentration to stop the reaction and the platinated DNA was precipitated by addition of sodium acetate (0.3 M) and ethanol. The pellets were rinsed with cold 75% (vol/vol) ethanol and dried (15). The ratio of bound platinum per nucleotide for both cis-and trans-DDP was determined by flameless atomic absorption spectroscopic analysis of carrier DNA platinated under identical conditions. Next, bleomycin A2 samples containing bound Fe(II) (2 and 4 u.M in two different experiments) and 2-mercaptoethanol (20 mM) in deaerated water were added to the platinated DNA dissolved in 20 mM Tris HCI buffer, pH 8.3, and the mixtures were incubated at 37°C for 10 min (327 bp) or 4 min (165 bp). A 10 ,uM solution of Na2EDTA was added to stop the reaction and the DNA was precipitated by addit...

show abstract

“…Using cisplatin alone or in combination with other chemotherapeutics can effectively kill rapidly malignant cells, and has been a routine option for systematic elimination of cancerous cells following surgeries and radiotherapies [5][6][7][8][9][10]. The antineoplastic activity of cisplatin is largely attributed to its property to bind to and crosslink DNA, and to inhibit transcription and/or DNA replication, thereby triggering an apoptotic program in the targeted cells [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

The formation of intracellular nanoparticles correlates with cisplatin resistance

et al. 2015

View full text Add to dashboard Cite

Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck

Cited by 19 publications

References 13 publications

Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program

Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program

Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II).

The formation of intracellular nanoparticles correlates with cisplatin resistance

Contact Info

Product

Resources

About